Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025HematologyOpen Access

Association between lymphocyte-associated ratios, C-reactive protein and prognostic value in myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHong-Kai CaiLJLin JiangJGJianbin Gong

Discussion

Loading...

Member takes

Overview

Observational analysis shows poor prognosis linked with C-reactive protein and lymphocyte ratios in MDS patients, suggesting relevance for clinical outcomes.

Key Points

  • High levels of C-reactive protein indicate a worse overall survival in MDS patients, with a median of only 28 months.
  • Favorable outcomes correlated with lymphocyte-associated ratios, as significant differences were noted in survival rates.
  • The study utilized the Kaplan-Meier method for survival analysis and X-tile software to determine cutoff points for inflammatory markers.
  • Elevated markers were found to be independent predictors of poor prognosis in newly diagnosed patients with myelodysplastic syndromes.

Cite This Study

Cai et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d6478fff2https://doi.org/10.1080/16078454.2025.2538950
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R2025 · 1 citations
  2. 2Prognostic Impact of Lymphocyte to Monocyte Ratio in Patients with Myelodysplastic Neoplasms/Syndromes2025
  3. 3From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS2025
  4. 4A prognostic model integrating disease‑ and patient‑oriented factors identifies poor‑outcome patients with low‑risk MDS: A multicenter real‑world cohort study (KOTOSG)2025
  5. 5Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma2025